Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study

Overview of attention for article published in Arthritis Research & Therapy, June 2016

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (72nd percentile)
Good Attention Score compared to outputs of the same age and source (70th percentile)

So far, Dimensions has found 58 publications that cite this research output.

Article in Current Opinion in Rheumatology (March 2024)

Article in Frontiers in Immunology (March 2024)

Article in Drug Safety (February 2024)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.